 | A major contributor to this article appears to have a close connection with its subject. (July 2018) |
Robert E. W. Hancock | |
|---|---|
 Hancock in 2016 | |
| Born | March 23, 1949 |
| Nationality | Canadian |
| Occupation | Professor |
| Awards | Officer of the Order of Canada, ICAAC Antimicrobial Research Award, Prix Galien, Order of British Columbia |
| Academic background | |
| Alma mater | University of Adelaide |
| Academic work | |
| Discipline | Microbiology and Immunology |
| Institutions | University of British Columbia |
| Notable ideas | Self-promoted uptake theory, Cationic peptides as immune modulators |
| Website | Hancock Lab Website |
Robert Ernest William Hancock OC OBC FRSC (born March 23, 1949) is a Canadian microbiologist and University of British Columbia Killam Professor of Microbiology and Immunology, an Associate Faculty Member of the Wellcome Trust Sanger Institute, and a Canada Research Chair in Health and Genomics.
Over his career he has published more than 800 papers and reviews, has 72 patents awarded, and is an ISI highly cited author in Microbiology with more than 113,000 citations and an h-index of 168. He has won several awards and is an Officer of the Order of Canada. He is a co-founder of Migenix, Inimex Pharmaceuticals, ABT Innovations, Sepset Biotherapeutics, and the Centre for Drug Research and Development. He serves as a member of the Scientific Advisory Board for Qu Biologics.[1]
- ^ "Scientific Advisory Board". Qu Biologics Inc. 2018-05-07. Archived from the original on 2023-05-07. Retrieved 2023-05-07.